HP&M’s Frank Sasinowski Added to Biotech Company’s “Wall of Honor”
October 29, 2010
On Thursday, United Therapeutics Corporation (“UTC”), a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions, unveiled a plaque honoring HP&M Director Frank Sasinowski for his contributions to UTC’s development of its REMODULIN (trepostinil) therapy for the rare, serious condition, pulmonary hypertension (View this photo). Others on that wall include Sir John Robert Vane, 1982 Nobel laureate for medicine and creator of this prostacyclin analog. Mr. Sasinowsi has been devoted to aiding in the development of orphan drugs since his days at FDA when he was key to implementing the Orphan Drug Act of 1983, including his work that led to the 1984 and 1985 amendments that gave this law its life. Mr. Sasinowski is Chair of the board of NORD, the National Oganization for Rare Disorders, which represents the 25 million americans with rare disorders.
